HER2 (ERBB2) Amplification
The HER2 (ERBB2) Human Epidermal growth factor Receptor 2 gene, located at chromosome band 17q12, is a member of the Epidermal Growth Factor (EGF) receptor family1.
It is activated and amplified in 20-30% of breast cancers2 and has been correlated with a poor prognosis for the patient3. Treatment of patients carrying the amplification using the monoclonal antibody Herceptin® (Trastuzumab) has been shown to be effective, increasing survival time by specifically targeting cells overexpressing HER24 and removing them from the system.
Similar results have been obtained for a variety of other malignant neoplasms overexpressing HER2 including ovarian5, stomach6, salivary gland7 and small cell lung8 cancers.
1. Coussens L, Yang-Feng TL et al., Science 1985;230(4730):1132-9
2. Slamon DJ et al., Science 1987;235(4785):177-82
3. López-Guerrero JA et al., Int J Cancer. 2006 Apr 1;118(7):1743-9
4. Kauraniemi P et al., Oncogene 2004;23(4):1010-3
5. Slamon DJ et al., Science 1989;244(4905):707-12
6. Gravalos C, Jimeno A, Ann Oncol 2008;19(9):1523-9
7. Vidal L et al., Head Neck 2009;31(8):1006-12
8. Ugocsai et al., Anticancer Res. 2005;25(4):3061-6
- Area of Interest*
- Breast Cancer, Gastric Cancer
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.